Securecell AG products

In its MedTech division, Securecell is proudly developing Seraccess®, an innovative technology that fully automates the high-frequency collection, processing, and analysis of blood using next generation microfluidics for the monitoring and controlling of critical blood parameters using the smallest blood sample possible. Seraccess® innovation begins with an ultra precise / fully automated Glucose ICU monitor and ends with a fully miniaturized / fully mobile artificial pancreas device for personalized life-changing glucose control.

Seraccess® was forged from Securecell’s expertise in automating and digitalizing the biotechnology space. Our immense knowledge of connecting expansive bioprocessing systems, microfluidics and documenting processes down to the molecular level led us to solutions that could greatly impact the Artificial Pancreas Device System (APDS) market for a significantly underserved diabetes community: unstable type 1 or 2 diabetes patients.¹